Related Experiment Video
Updated: May 24, 2025
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
Beta-Hydroxybutyrate Attenuates Bronchial Smooth Muscle Pro-Inflammatory Cytokine Production
V Amanda Fastiggi1,2, Madeleine M Mank1, Matthew E Poynter1
1Department of Medicine, Division of Pulmonary Disease and Critical Care, University of Vermont, and The Vermont Lung Center, Burlington, VT, 05405, USA.
Therapeutic ketosis, using beta-hydroxybutyrate (BHB), may reduce asthma symptoms. BHB targets bronchial smooth muscle cells, suppressing inflammation and bronchoconstriction, offering a potential new treatment for difficult-to-treat asthma.
Area of Science:
- Immunology
- Respiratory Medicine
- Metabolic Science
Background:
- Asthma involves airway inflammation and bronchoconstriction, often exacerbated in obese individuals.
- Bronchial smooth muscle (BSM) cells contribute to airway narrowing and inflammation in asthma.
- Current asthma treatments are insufficient for some patients, especially those who are obese and allergic.
Purpose of the Study:
- To investigate the potential of beta-hydroxybutyrate (BHB) in mitigating asthma symptoms.
- To determine if BHB can reduce inflammation and bronchoconstriction by targeting bronchial smooth muscle.
Main Methods:
- Utilized human bronchial smooth muscle cells (HBSMC) in vitro.
- Examined the effect of BHB on IL-1β-induced pro-inflammatory cytokine production.
- Investigated the role of Free Fatty Acid Receptor 3 (FFAR3) in mediating BHB's effects.
Main Results:
- BHB significantly suppressed IL-1β-induced pro-inflammatory cytokine production in HBSMC.
- This suppression was mediated through the activation of FFAR3.
- Demonstrated that bronchial smooth muscle is a viable target for BHB therapy.
Conclusions:
- BHB shows promise in reducing airway inflammation and bronchoconstriction in asthma.
- Targeting bronchial smooth muscle with BHB may offer a novel therapeutic strategy.
- Therapeutic ketosis, via BHB, could be beneficial for managing difficult-to-treat asthma, particularly in obese individuals.
More Related Videos
08:42Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
Published on: May 26, 2023
08:33A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: